Amgen Wins Patent Case Over Sanofi & Regeneron

[mango]

Feel free to move this thread if need be. Thought most would be interested in this.

— "On Tuesday, Amgen kept the upper hand in that patent case, which could put the company in line to collect royalties from Sanofi's and Regeneron's treatment."

— "A Sanofi spokeswoman said the company is disappointed with the ruling. "It is our longstanding position that Amgen’s asserted patent claims are invalid, and we intend to appeal today’s ruling," she said via email."

— "An Amgen spokeswoman, however, called judge's decision "an important step in this case." The ruling "confirms the jury's finding that the patents which protect Repatha are valid and infringed by Sanofi," the spokeswoman said, as quoted by Reuters."

— "Damages have not yet been determined in the patent case. And Robinson has yet to decide whether to halt Praluent sales. If the case resolves with a royalty agreement instead, and sales pick up, Amgen could be in good shape. A year ago, investment bank Chardan predicted that Amgen would prevail in the case and receive 10% to 20% of Praluent’s sales."

www.fiercepharma.com/pharma/judge-upholds-pcsk9-patent-ruling-amgen-s-favor-as-sanofi-regeneron-get-set-to-appeal

[lakers]

Amgen shares soar as judge blocks sales of Regeneron drug

By Wallace Witkowski

Published: Jan 5, 2017 6:09 p.m. ET

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.57% were halted in the extended session Thursday while shares of Amgen Inc. AMGN, +0.07% rallied after a federal judge said Regenron had to pull its competing cholestrol drug off the market as a penalty in a patent lawsuit. Regeneron shares were halted at $376.61, down 1.1% after hours, while shares of Amgen jumped 4.6% to $160. On Thursday, a federal judge blocked sales of Regeneron's cholesterol treatment Praluent, stating that "irreparable harm" had been done to Amgen's Repatha.

www.thestreet.com/story/13944621/1/regeneron-cholesterol-lowering-drug-banned-from-u-s-market-in-stunning-loss-to-amgen-in-patent-case.html

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market in Stunning Loss to Amgen in Patent Case

A federal judge has banned the sale of Regeneron'S cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

A federal judge has banned the sale of Regeneron Pharmaceuticals' (REGN) cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen (AMGN) and its competing drug Repatha in a long-running patent lawsuit.

Amgen had already won the trial in which Regeneron was shown to have infringed on its patents covering a class of cholesterol-lowering drugs known as PCSK9 inhibitors.

Thursday's night ruling by the judge in the case centered on the penalty Regeneron would have to pay to Amgen. Most investors believed the judge would require Regeneron to pay a royalty on sales of Praluent back to Amgen but would otherwise allow the drug to remain on the market.

The judge went further, ruling Regeneron "demonstrated irreparable harm" to Amgen and that money damages were inadequate compensation. Regeneron must stop selling Praluent in the U.S., although the ban has been delayed 30 days to allow the company to appeal.

Amgen shares rose 5% to $160.54 following the dissemination of the judge's ruling. Regeneron shares were halted at $380.92.

"Running numbers on the back of the envelope, we estimate that if Praluent was gone from the market the long term peak sales for Repatha (Amgen) could move from $2B to $3-4B WW, in theory," said RBC Capital Market biotech analyst Michael Yee, in a note issued after the ruling.

Sales of both Praluent and Repatha have been minimal to date because insurance companies have largely refused to provide reimbursement. Amgen and Regeneron are conducting separate follow-on studies aimed at demonstrating the use of PSCK9 inhibitors to lower cholesterol levels also provide more substantive benefits to patients in the form of lower rates of heart attacks, strokes and death.

Results from these cardiovascular outcomes studies are expected relatively soon.

With today's injunction barring Regeneron from selling Praluent, the potential jackpot awaiting Amgen if its Repatha outcomes study is positive becomes even larger.

[kc]

I guess that I should have posted here:

Bad Karma? or just the Devil getting his due from Sanofi.







www.reuters.com/article/us-sanofi-fr-amgen-idUSKBN14P2IY




Seems that Sanofi gets a good judgment.




U.S. judge blocks Sanofi, Regeneron from selling cholesterol drug





A federal judge on Thursday blocked Sanofi SA and Regeneron Pharmaceuticals Inc from selling their cholesterol drug Praluent, a victory for Amgen Inc, which had accused them of infringing its patents.

U.S. District Judge Sue Robinson in Delaware ordered that the ban not take effect for 30 days to give Sanofi and Regeneron time to appeal.

Amgen was up 4.9 percent in after hours trading, while Sanofi's U.S. shares and Regeneron were down 4 and 1.1 percent, respectively.




More at link above Reuters link.


Read more: mnkd.proboards.com/thread/3846/afrezza-insulin-human-intervention-alirocumab?page=4#ixzz4Uvum36cb